Pell Bio Med Unit Gets China's Regulatory Nod for Rheumatoid Arthritis Drug Trail
MT Newswires Live
Jun 03
Pell Bio Med Technology (TPE:6949) unit Peptide (Shanghai) Pharmaceutical Technology secured approval from China's National Medical Products Administration (NMPA) to begin the Phase I clinical trial for its oral drug candidate PP011, according to a Tuesday Taiwan Exchange filing.
The trial will be conducted in healthy subjects and targets rheumatoid arthritis (RA), marking the first human study for the novel therapy.
The company said the development program is planned through Phase two and Phase three trials before potential new drug application submission.
Phase one completion is expected in the first quarter of 2027, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.